Isoray’s Cesium-131 Spotlighted in Multiple Presentations at ASTRO

Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World’s Premier Radiation Oncology Society RICHLAND, WASHINGTON – November 24, 2020 – The importance of Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate and brain...

Isoray Announces First Quarter Fiscal 2021 Financial Results

Revenue Increased 3% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 104% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...

Isoray, Inc. Announces Pricing of $9.5 Million Public Offering

RICHLAND, Wash., October 20, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 18,269,230 shares of...

Isoray, Inc. Announces Proposed Underwritten Public Offering

RICHLAND, Wash., October 19, 2020 — Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer...